ProCE Banner Activity

Mezigdomide Plus Vd or Kd in Relapsed/Refractory Multiple Myeloma: Updated Results From the CC-92480-MM-002 Phase I/II Trial

Conference Coverage
Slideset

An updated analysis from the phase I/II CC-92480-MM-002 dose escalation/expansion trial of mezigdomide plus bortezomib and dexamethasone (Vd) or carfilzomib and dexamethasone (Kd) in relapsed or refractory MM showed a manageable safety profile and promising efficacy.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation